Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.
Roa P, et al. Among authors: harada g.
Br J Cancer. 2024 Aug;131(3):601-610. doi: 10.1038/s41416-024-02760-1. Epub 2024 Jun 20.
Br J Cancer. 2024.
PMID: 38902532
Free PMC article.